Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 12;18(1):94.
doi: 10.1186/s12902-018-0322-7.

Radioiodine treatment for graves' disease: a 10-year Australian cohort study

Erin Fanning  1   2 , Warrick J Inder  3   4 , Emily Mackenzie  5   6
Affiliations

Radioiodine treatment for graves' disease: a 10-year Australian cohort study

Erin Fanning et al. BMC Endocr Disord. .

Abstract

Background: Radioactive iodine (I131) is a common definitive treatment for Graves' Disease. Potential complications include worsening, or new development of Graves' eye disease and development of a radiation thyroiditis. The purpose of the present study was to assess outcomes of patients treated with I131 in an Australian tertiary centre over 10 years.

Methods: Data from 101 consecutive patients treated with I131 for a diagnosis of Graves' disease between 2005 to 2015 was collected and reviewed retrospectively. Baseline TSH receptor antibody titre, pre-treatment free thyroxine (FT4), technetium scan uptake, initial treatment, duration of treatment, reason for definitive therapy, complications, and time to remission (defined as euthyroidism or hypothyroidism after 12 months) were recorded.

Results: Of the 92 patients with adequate outcome data, 73 (79.3%) patients achieved remission with a single dose of I131. Of the remaining 19 patients, 12 had a second dose and became hypothyroid. TSH receptor antibody titre at diagnosis was significantly lower in the group that achieved remission with the first dose compared with those who did not (P = 0.0071). There was no difference in technetium uptake, I131 dose, duration of therapy or pre-treatment free thyroxine (FT4). I131 was complicated by development of eye disease in 3 patients and 1 (of 11 with pre-existing eye disease) had worsening eye disease. A clinically apparent flare of hyperthyroidism following I131 was evident in 8 patients (8.6%).

Conclusion: Radioiodine is an effective therapy for Graves' Disease with few complications. The majority of patients achieve remission with a single dose. Those who require a second dose are more likely to have higher TSH receptor antibody titres at diagnosis. To the best of our knowledge, this is the first study to report outcomes from radioiodine treatment for Graves' disease in an Australian population.

Keywords: Graves’ disease; Graves’ disease treatment.; I131.; radioiodine..

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Ethics approval was obtained from the Metro South Human Research Ethics Committee (Reference number: LNR/QMS/43580). All necessary permissions to access medical records from the Princess Alexandra Hospital were obtained. Consent to participate was not a requirement.

Competing interests

The authors declare they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Outcomes in 101 patients with Graves’ disease treated with radioactive iodine
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Burch HB, Cooper DS. Management of Graves Disease A Review. JAMA. 2016;314:2544–2554. doi: 10.1001/jama.2015.16535. - DOI - PubMed
    1. Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med. 2011;364:542–550. doi: 10.1056/NEJMct1007101. - DOI - PubMed
    1. Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol. 2004;61:641–648. doi: 10.1111/j.1365-2265.2004.02152.x. - DOI - PubMed
    1. Zantut-Wittmann DE, Ramos CD, Santos AO, Lima MMO, Panzan AD, Facuri FVO, et al. High pre-therapy [99mTc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors of failure in [131I]iodide therapy in Graves’ disease. Nucl Med Commun. 2005;26:957–963. doi: 10.1097/01.mnm.0000183795.59097.42. - DOI - PubMed
    1. Topliss DJ, Eastman CJ. Diagnosis and management of hyperthyroidism and hypothyroidism. Med J Aust. 2004;180:541–542. - PubMed

Substances

LinkOut - more resources